ArticleBMC infectious diseases2025
Effectiveness of voriconazole therapy for pulmonary cryptococcosis in fluconazole treatment failure: a multicenter real-world study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurrent guidelines recommend fluconazole as first-line therapy for pulmonary cryptococcosis. However, clinical reports indicate that fluconazole treatment fails in some patients. Voriconazole is frequently used in these cases, yet its effectiveness has not been comprehensively studied or validated.
methodThis multicenter real-world retrospective study enrolled patients with fluconazole treatment failure who were divided into two groups based on subsequent antifungal therapy: continuation of fluconazole or switch to voriconazole. Overall treatment responses were evaluated at predetermined endpoints for both groups, with safety outcomes also assessed.
resultInitial fluconazole treatment achieved success in 82.72% of patients. Among patients with fluconazole treatment failure, 19 were assigned to the control group (continued fluconazole) and 15 to the voriconazole group. At day 60, the voriconazole group demonstrated a significantly higher response rate compared to the fluconazole group (66.67% [n = 10] vs. 15.79% [n = 3], p = 0.002). However, at day 180, response rates were comparable between groups (66.67% [n = 10] vs. 68.42% [n = 13], p = 0.914). The incidence of adverse reactions did not differ significantly between groups (20.00% [n = 3] vs. 15.79% [n = 3], p = 0.439).
conclusionThe majority of patients achieved favorable therapeutic outcomes with initial fluconazole treatment. In patients experiencing fluconazole treatment failure, switching to voriconazole demonstrated superior short-term efficacy compared to continued fluconazole therapy; however, long-term outcomes were comparable between the two treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.